UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 9, 2018

HALOZYME THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	**001-32335**	**88-0488686**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

11388 Sorrento Valley Road, San Diego, California	**92121**
(Address of principal executive offices)	**(Zip Code)**

Registrant's telephone number, including area code: (858) 794-8889

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On January 9, 2018, Halozyme Therapeutics, Inc., a Delaware corporation ("Halozyme"), issued a press release (the "Press Release") which contained information related to Halozyme's expected 2017 royalty revenue and year-end cash balance. A copy of the Press Release is attached hereto as Exhibit 99.1.

On January 9, 2018, Halozyme presented at the annual JP Morgan Healthcare Conference, providing a corporate update on certain strategic programs and financial guidance for 2018. The presentation contained information related to various aspects of Halozyme's expected 2017 results of operations and financial condition. A copy of the slides used in this presentation is attached hereto as Exhibit 99.2.

Exhibits 99.1 and 99.2 are furnished under Item 2.02 of this report and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 7.01 Regulation FD Disclosure.

The Press Release and slides from the JP Morgan Healthcare Conference presentation attached hereto as Exhibits 99.1 and 99.2, respectively, provide a corporate update on certain strategic programs and financial guidance for 2018 and are incorporated herein by reference. The slides attached hereto as Exhibit 99.2 (as well as the information contained therein) are expected to be used in subsequent presentations to interested parties, including analysts and stockholders.

This information is being furnished pursuant to Item 7.01 of this Report and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by Halozyme, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference. This Report will not be deemed an admission as to the materiality of any information in this Report that is being disclosed pursuant to Regulation FD.

Please refer to the Press Release attached hereto as Exhibit 99.1 and slide 2 of the presentation attached hereto as Exhibit 99.2 for a discussion of certain forward-looking statements included therein and the risks and uncertainties related thereto.

Item 9.01. Financial Statements and Exhibits.

Exhibits

Exhibit No.	Description
99.1	Press release dated January 9, 2018
99.2	Halozyme Therapeutics, Inc. corporate update presentation dated January 9, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Halozyme Therapeutics, Inc.

January 9, 2018

By: */s/ Harry J. Leonhardt, Esq.*

Harry J. Leonhardt, Esq.

Senior Vice President, General Counsel,
Chief Compliance Officer and Corporate Secretary

Exhibit Index

Exhibit No.	Description
99.1	Press release dated January 9, 2018
99.2	Halozyme Therapeutics, Inc. corporate update presentation dated January 9, 2018

EXHIBIT 99.1

Contacts:
Jim Mazzola
858-704-8122
ir@halozyme.com

Chris Burton
858-704-8352
ir@halozyme.com

HALOZYME PORJECTS 25 TO 30 PRECENT ENHANZE ROYALTY GROWTH IN 2018

CONTINUES TO EXPECT TARGET NUMBER OF PFS EVENTS IN HALO-301 REGISTRATION TRIAL TO BE REACHED IN LATE Q4

SAN DIEGO, Jan. 9, 2018 - Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, forecasts 25 to 30 percent royalty revenue growth in 2018 and potential for royalty revenue to reach nearly $1 billion in 2027 based on the current and expected momentum of partners coformulating products with its ENHANZE ® technology.

Halozyme provided these and other program updates today during CEO Dr. Helen Torley's presentation at the 36 th annual JP Morgan Healthcare Conference.

"We enter 2018 building on the most successful year in Halozyme history, where we established our ENHANZE technology as the go-to standard to convert IV therapies to subcutaneous delivery, potentially helping our partners improve their competitive advantage and easing the treatment burden for patients," said Dr. Torley. "With this momentum and the marquee therapies under development or planned for development with ENHANZE - including subcutaneous formulations of Darzalex, a Herceptin/ Perjeta fixed-dose combination and Opdivo - we now see the potential for ENHANZE royalty revenue to reach nearly $1 billion in 2027."

Janssen initiated four phase 3 registration studies with ENHANZE in 2017, and Halozyme expects additional partners to begin three phase 1 studies with new targets in 2018. The breadth of clinical development with the ENHANZE technology follows the signing of three global collaboration and licensing agreements in 2017. In total, Halozyme now has eight partners with the potential to generate an average mid-single-digit royalty on net sales of commercialized products.

Three commercialized products coformulated with the ENHANZE technology generated $64 million in royalty revenue in 2017, growing 25 percent from 2016, Dr. Torley said. The company expects to report fourth quarter and 2017 financial results in February.

Halozyme also provided updates on the clinical development of its late-stage investigational oncology drug, PEGPH20 (pegvorhyaluronidase alfa), including its HALO-301 registration trial in metastatic pancreatic cancer patients. As previously announced, the company expects the study will reach the target number of progression-free survival events late in the fourth quarter.
In addition, Halozyme may report phase 1b response rate data during the year from two other clinical trials studying PEGPH20 in additional tumor types. Between Halozyme- and partner-led trials, PEGPH20 is being studied in pancreas, gastric, lung, breast, gall-bladder and bile-duct cancers.

Dr. Torley said the company exited 2017 with $460 million to $470 million in cash and cash equivalents and is well financed into 2020. Financial guidance for 2018 was provided during her presentation, a replay of which may be found on the “Investors” page of halozyme.com.

About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme’s lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb and Alexion for its ENHANZE ® drug delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

###

Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements concerning the Company’s future expectations and plans for 2018, timing and results of clinical trials, the development and commercialization of product candidates and the potential benefits and attributes of such product candidates (including, without limitation, statements concerning the possible activity, benefits and attributes of PEGPH20, the possible method of action of PEGPH20, its potential application to improve cancer therapies and statements concerning future actions relating to the development of PEGPH20). These statements also include forward-looking statements concerning the possible activity, benefits and attributes of the company’s ENHANZE technology, the possible method of action of ENHANZE, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, the number of collaborative targets actually chosen, the product development efforts of our ENHANZE partners, whether such products are ultimately developed or commercialized, whether milestones triggering milestone payments will be achieved, and statements concerning facilitating more rapid delivery of injectable medications through subcutaneous delivery. The forward looking statements also include the Company’s expected financial outlook, including expectations for royalty revenue growth in 2018 and beyond. These forward looking statements involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends,"

"estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected fluctuations or changes in revenues from collaborators or product sales, unexpected clinical trial delays or results, including enrollment delays, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission.

Halozyme

JP Morgan 36th Annual Healthcare Conference

Building a Premier Oncology Biotech

Dr. Helen Torley, President & CEO

January 9, 2018

Forward-Looking Statements

All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such statements include possible activity, benefits and attributes of PEGPH20, future product development and regulatory events and goals, anticipated clinical trial results and strategies, product collaborations, our business intentions and financial estimates and results, including projected revenue amounts. These statements are based upon management's current plans and expectations and are subject to a number of risks and uncertainties which could cause actual results to differ materially from such statements. A discussion of the risks and uncertainties that can affect these statements is set forth in the Company's annual and quarterly reports filed from time to time with the Securities and Exchange Commission under the heading "Risk Factors." The Company disclaims any intention or obligation to revise or update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Halozyme Two Pillar Strategy

Removing Biological Barriers to Treatment



ENHANZE®

Enhancing Delivery of Treatments

PEGPH20

Late Stage Investigational New Product

ENHANZE image from "The 5 Steps to Infuse HYQVIA." *http://www.hyqvia.com/resources/videos/*

Significant Value Creation in 2017

ENHANZE®

- 2 new partners: BMS, Alexion
- Roche adds new target
- $175M upfront milestones
- Phase 3 starts: Janssen's Darzalex®

Financial

- Cash balance exiting 2017 of $460M-$470M

PEGPH20 - Pancreatic

- Supportive Phase 2
- Companion Diagnostic
- Strong progress in Phase 3 trial: HALO-301

PEGPH20 - Pan-Tumor

- > 20 patients enrolled: Keytruda®/PEGPH20
- 2 studies in 4 tumors: Tecentriq®/PEGPH20

Capabilities

- Initiating > 200 centers in 22 countries in Phase 3 Pancreas Cancer Trial
- Agreements and onboarding of 2 new partners
- Record number of API lots delivered

Halozyme

ENHANZE® Pillar

2017: Transformative Year for ENHANZE® Pipeline

- **June 2017:** RITUXAN HYCELA™ U.S. FDA Approval
- **Aug 2017:** Initiate Phase 1 trial
- **Sept 2017:** Landmark 11-target I-O deal
- **Sept 2017:** Expanded collaboration, 1 new target
- **Nov 2017:** Initiate Phase 3 trials, daratumumab SC
- **Dec 2017:** Four-target collaboration

Commercial Products Driving Robust ENHANZE® Royalty Growth

Growing Royalty Revenue

Average Mid-Single Digit Royalty Rate Across Partnerships



Ex-U.S. Launch

Herceptin SC trastuzumab subcutaneous

HyQvia Human Normal Immunoglobulin (10%) Recombinant Human Hyaluronidase

MabThera SC Rituximab Subcutaneous FAST · EASY · EFFECTIVE

U.S. Launch

HyQvia Human Normal Immunoglobulin (10%) Recombinant Human Hyaluronidase

6/17[1]

RituxanHYCELA rituximab/hyaluronidase human subcutaneous injection

Halozyme

[1] Quarterly reporting lag in 2017; expect to see revenue reflected in 2018.
[2] 2017 total royalty revenue, unaudited.

ENHANZE®: ~$1 Billion Royalty Revenue Potential in 2027



Approved Products

RituxanHYCELA (rituximab/hyaluronidase human)

Herceptin SC (trastuzumab)

MabThera SC (Rituximab Subcutaneous) FAST · EASY · EFFECTIVE

HyQvia (Human Normal Immunoglobulin (10%) Recombinant Human Hyaluronidase)

Potential Future Products[1,2]

Assumes 7 additional products, including Darzalex® and Opdivo®, are globally approved and launched in multiple indications

Halozyme

[1] Includes projections for subcutaneous versions of 7 targets not approved or commercially available. Innovator revenues based on Bloomberg analyst projections. Conversion rates based on Halozyme internal projections.
[2] Royalty revenue projection includes targets selected but not yet disclosed.

ENHANZE® Progress and Value Acceleration in 2018

2017

6 Products



2018

9 products



- Approved and Commercialized
- Phase 1
- Phase 3

Halozyme

ENHANZE® Offers Four Paths for Differentiation and Value Creation for Partners

Halozyme

Phase 3 Oncology Asset: PEGPH20

Pancreatic Ductal Adenocarcinoma (PDA): The Need

- **65,000** people diagnosed with metastatic pancreas cancer each year[1]
- **55,250** will die within 12 months of diagnosis[2]
- **By 2030**, pancreas cancer projected to be the 2nd leading cause of cancer death[3]
- High levels of **Hyaluronan (HA)** associated with poor survival in pancreas cancer[4]

Halozyme

[1] SEER 18 2006-2012, Globocan 2012, DRG Epidemiology data.
[2] Statistics adapted from the American Cancer Society's publication, Cancer Facts & Figures 2016.
[3] Rahib et al, Cancer Res 2014.
[4] Whatcott, et al. AACR (2013)

PEGPH20 Targets and Degrades Hyaluronan

Before PEGPH20[1]



- Hard
- Fibrotic
- Hypovascular

After PEGPH20[1]



- Soft
- Cellular
- Hypervascular

[1] Provenzano, et al. Cancer Cell. 2012;21(3):418.

~$1B Potential Sales Opportunity in HA-High Metastatic Pancreatic Ductal Adenocarcinoma (PDA)

65,000

Diagnosed Metastatic PDA Annually US and EU 5[1]

25,000

Estimated number of HA-High patients

35-40% of population[2]

~$1B

Projected potential global sales opportunity for successful therapy in metastatic PDA[3]

Halozyme

[1] SEER 18 2006-2012, Globocan 2012, DRG Epidemiology data.
[2] Halozyme estimates for HA-High %.
[3] DRG Epidemiology data, Halozyme internal estimates.

PEGPH20 Pancreas Cancer Program
De-risking Event Timeline

2013–2015
- Phase 2 HALO-202 study initiated

2016
- Companion Diagnostic algorithm and cutpoint established
- Initiated Phase 3 HALO-301 study

2017
- HALO-202 data supportive of Phase 3 trial design
- Validated companion diagnostic
- HALO-301 ongoing at >200 centers in 22 Countries

2018
- Project target PFS events late Q4 2018 with data to follow

HALO-301 | Pancreatic: Global Phase 3 Trial Enrolling in 22 Countries



Primary Endpoints:

- Progression-Free Survival (PFS)
- Overall Survival (OS)

- Randomized (2:1 PAG:AG), double-blind, placebo-controlled, global
- Project to achieve target number of PFS events late Q4 2018, triggering final data collection, cleaning and interim analysis

Estimated Annual HA-High Patients in Multiple Tumor Types[1]



[1] DRG Epidemiology data, Halozyme estimate for HA-High %.

Robust Pan-Tumor Testing of PEGPH20

Combination	Tumor		
Chemotherapy			
Eribulin (Halaven®) *Eisai led*	**Breast Cancer**	Phase 1b Dose Finding	Data Update in 2018
Checkpoint Inhibitors			
Pembrolizumab (Keytruda®)	**Gastric Cancer, NSCLC**	Phase 1b Dose Expansion Started Jan 2017	Data Update in 2018[1]
Atezolizumab (Tecentriq®) *Roche*	**Pancreas Cancer, Gastric Cancer**	Phase 1b Dose Finding Started 2H 2017	
Atezolizumab (Tecentriq)	**Gall Bladder Cancer, Cholangiocarcinoma**	Phase 1b Dose Finding Started 2H 2017	

ISTs: SWOG study enrollment closed in March 2017 following futility analysis in all-comer population. Data collection and analysis ongoing.

[1] Pending continued enrollment rate.

Halozyme

Financial Update

Record 2017 Financial Performance

	Jan 2017	2017 FY Estimate	
Net Revenue	$115M to $130M	**$310M to $320M**	New ENHANZE® agreements: $172M
Operating Expenses	$240M to $250M	**$230M to $240M**	Disciplined expense control, flat spending to 2016
Operating Cash (Burn) / Flow	($75M to $85M)	**$125M to $135M**	Excludes impact of financing, repayment of debt principal
Year-end Cash	$100M to $110M	**$460M to $470M**	New ENHANZE revenue, $135M equity raise

2018 Financial Guidance

	2018	
Net Revenue • **Royalty Growth** • **Product Sales**	$115M to $125M 25% - 30% API product orders lower as a result of planned partner manufacturing transition	• Does not include potential new ENHANZE® agreements
Operating Expenses	$230M to $240M	• Disciplined expense control, flat to 2017
Operating Cash Burn	($75M) to ($85M)	• Excludes impact of financing, repayment of debt principal
Debt Repayment	~($95M)	• Includes royalty-backed and Oxford/SVB loans
Year-end Cash	$305M to $315M	• Cash runway into 2020

Core Elements of Value Creation in 2018

ENHANZE®

- 25%-30% Royalty Revenue Growth
- Multiple catalysts
  - 3 Phase 1 starts
  - 4 Phase 3 Darzalex® trials
- ~$1B royalty potential in 2027

PEGPH20 - Pancreatic

- Q4 2018 Phase 3 PFS Events milestone
- ~$1B potential sales opportunity

Financial

- Cash balance exiting 2018 of $305M-$315M

PEGPH20 - Pan-Tumor

- Potential data from two trials

Capabilities

- Readiness for PEGPH20 BLA/MAA submissions in 2019
- Support ENHANZE partner progress

Halozyme

JP Morgan 36th Annual Healthcare Conference

Building a Premier Oncology Biotech

Dr. Helen Torley, President & CEO

January 9, 2018